Arrowhead Pharmaceuticals Inc (FRA:HDP1)
€ 24.66 4.54 (22.56%) Market Cap: 3.08 Bil Enterprise Value: 2.92 Bil PE Ratio: 0 PB Ratio: 17.54 GF Score: 48/100

Arrowhead Pharmaceuticals Inc R&D Day Transcript

Jun 01, 2023 / 01:00PM GMT
Release Date Price: €31.99 (+2.34%)
Vincent Anzalone
Arrowhead Pharmaceuticals, Inc. - Head of IR & VP

Thanks so much for coming today. We're here for Arrowhead's Analyst R&D Day, and we have a lot to cover. So I'm just going to jump in. This is our safe harbor statement. Please refer to the risk factors in our SEC filings. We will be making forward-looking statements in today's presentations. So we've got a really good panel. Arrowhead folks as well as a few external folks who are experts in their disease areas. We have Michael Benatar from the University of Miami, who'll be talking about ALS and SOD1 specifically. We have Matthias Salathe from University of Kansas, who will be talking about the pulmonary programs, both inflammatory as well as the muco-obstructive program; and Ira Goldberg from NYU, who'll be talking about the cardiometabolic.

So like I said, there's a lot to cover today. This is the basic flow. We'll go over CNS. We'll go over some of the expansion that we're doing to the TRiM platform to get to new tissue types. Then we'll have a Q&A session in between each kind of topical area, short Q&A, about

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot